Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHIT1 | Q13231 | 9/20 | 0.40 |
| ▸ | CHIA | Q9BZP6 | 6/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.38 |
| ▸ | CHI3L1 | P36222 | 4/20 | 0.36 |
| ▸ | CHI3L2 | Q15782 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25385125 | 0.87 | CHIT1 (0.42) | CHIT1CHIAKCNH2CHI3L1CHI3L2 | |
| SCHEMBL26605744 | 0.85 | CHIT1 (0.50) | CHIT1CHIAKCNH2CHI3L1CHI3L2 | |
| SCHEMBL26707882 | 0.85 | CHIT1 (0.37) | CHIT1CHIAKCNH2CHI3L1TSHR | |
| SCHEMBL26706003 | 0.85 | CHIT1 (0.37) | CHIT1CHIAKCNH2CHI3L1TSHR | |
| SCHEMBL18577375 | 0.85 | CHIT1 (0.53) | CHIT1CHIAKCNH2CHI3L1CHI3L2 | |
| SCHEMBL18577289 | 0.84 | CHIT1 (0.42) | CHIT1CHIAKCNH2CHI3L1CHI3L2 | |
| SCHEMBL26605644 | 0.82 | CHIT1 (0.41) | CHIT1CHIAKCNH2CHI3L1CHI3L2 | |
| SCHEMBL26605591 | 0.82 | CHIT1 (0.45) | CHIT1CHIAKCNH2CHI3L1CHI3L2 | |
| SCHEMBL26605535 | 0.81 | CHIT1 (0.46) | CHIT1CHIAKCNH2CHI3L1CHI3L2 | |
| SCHEMBL26605678 | 0.81 | CHIT1 (0.54) | CHIT1CHIAKCNH2CHI3L1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348516-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | MOLECURE S.A. (PL) | 2023-11-02 | — | — | US | disclosed |
| EP-4269400-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | Molecure SA (PL) | 2023-11-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348516-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | CHI3L1, CHI3L2, CHIA | CHIT1 4/4885CHIA 3/4885KCNH2 4518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.